Brand Strategy : Building Demand

Market Shaping in Pharma: How to Create Demand Before Your Drug Is Approved

Understanding how pharma brands build prescriber readiness and close diagnosis gaps before regulatory approval — with proven Indian market examples.

Executive Summary (TL;DR)

Market Shaping Definition: Market shaping creates prescriber demand 18-24 months before drug approval by identifying diagnosis gaps, educating HCPs on disease burden, and priming treatment pathways — happening before launch, not after, unlike post-launch disease awareness campaigns.

Strategic Timing: Indian pharma leaders launch market shaping during Phase 3 trials, using unbranded disease education to build HCP awareness while competitors remain focused on existing therapies.

Competitive Intelligence Foundation: Successful market shaping requires competitive intelligence on current treatment patterns, diagnosis gap analysis, and HCP priming strategy to ensure launch readiness when DCGI approval arrives.

OneAlphaMed Research Desk

Pharma & Life Sciences Practice • Brand Strategy Intelligence

Updated:April 14, 2026

7 min read

Fig 1. Market shaping builds prescriber demand before approval through unbranded HCP education and strategic priming.

Market shaping creates prescriber demand before DCGI approval — not after. Most pharmaceutical companies wait until regulatory approval to activate commercial teams, creating a critical gap. By the time approval arrives, competitors have already captured prescriber mindshare, and HCPs remain unaware of the disease burden your therapy addresses. Market shaping eliminates this lag by building clinical urgency 18-24 months before launch.

Market shaping eliminates this lag. Leading pharma brands now invest 18-24 months before approval to educate HCPs on unmet medical needs, identify diagnosis gaps, and prime treatment pathways. This pre-launch planning transforms launch outcomes. When your product receives approval, prescribers already recognize the clinical problem and actively seek solutions.

Indian pharma companies increasingly deploy market shaping strategies across therapeutic areas. Understanding the distinction between market shaping and traditional disease awareness campaigns — and knowing when to activate each strategy — now defines competitive advantage in brand strategy and product launch execution.

1. What Market Shaping Actually Means (Before Approval)

Market shaping identifies clinical gaps in current treatment paradigms and educates stakeholders on disease burden before your product launches. This strategy operates through unbranded disease education rather than product promotion. Medical Affairs teams work with KOLs to publish epidemiological data, highlight diagnosis challenges, and establish treatment guidelines.

The core mechanism differs fundamentally from post-launch tactics. Market shaping creates the clinical conversation that your product will eventually address. You invest resources to demonstrate that current therapies leave patient populations underserved, diagnostic criteria remain inconsistent, or treatment adherence faces systemic barriers.

Consider a novel biologic for autoimmune disease entering the Indian market. Market shaping begins by funding research on diagnosis rates across tier-2 and tier-3 cities, sponsoring medical education on disease recognition, and supporting HCP training programs. These initiatives build awareness of the clinical problem — not your specific solution.

Key Insight

"Pharma brands that launch market shaping 18-24 months before approval capture 40-60% higher first-year market share compared to competitors entering the same indication without pre-launch priming. HCPs prescribe therapies they already understand."

2. Disease Awareness vs Market Shaping

Disease awareness campaigns target patients and caregivers to drive consultation requests. These initiatives run post-launch to increase therapy adoption among diagnosed populations. Market shaping targets prescribers before approval to establish clinical urgency and treatment readiness.

The timing separates these strategies fundamentally. Disease awareness begins after you hold regulatory approval and can legally discuss your product. Market shaping operates in the pre-approval window when branded messaging remains prohibited but unbranded education faces no restrictions.

Audience focus also differs sharply. Disease awareness campaigns use patient testimonials and symptom checkers to build patient demand. Market shaping deploys competitive intelligence and epidemiological research to build prescriber demand. One pulls patients into clinics; the other primes clinicians to recognize and treat.

3. Strategic Value Across Product Lifecycle

Market shaping delivers measurable value at every product lifecycle stage, transforming the trajectory of a brand well before the first prescription is written:

Phase 3 Priming: Unbranded disease education builds HCP familiarity with your target indication, eliminating the educational lag competitors face.
Launch Acceleration: At launch, market shaping converts into immediate prescribing behavior because HCPs already understand the clinical problem and seek solutions.
Post-Launch Returns: The infrastructure built—such as diagnosis gap analysis—becomes the foundation for targeted HCP outreach and payer negotiations.

4. Core Market Shaping Strategies

Successful market preparation requires a multi-pronged approach to address existing clinical gaps:

Diagnosis Gap Analysis: Quantifying the difference between disease prevalence and diagnosis rates to build the clinical case for improved screening.
Unbranded Disease Education: Using CME sessions and clinical case studies to establish medical need without mentioning a specific product.
HCP Priming Strategy: Engaging thought leaders and early adopters early to create advocates who drive adoption within their networks post-approval.
Competitive Intelligence Integration: Analyzing competitor messaging to identify gaps and position your disease education to address unmet needs others ignore.

Ready to build your pre-launch market shaping strategy?

Explore our Brand Strategy & Product Launch services →

5. Indian Pharma Market Examples

In India, market shaping is becoming the gold standard for high-stakes launches across various therapeutic areas:

Oncology Biosimilars: Manufacturers fund screening camps in tier-2 cities and train oncologists on biomarker testing 24 months before launch.
Diabetes Management: Leading brands sponsor HbA1c screening programs and train primary care physicians on detection protocols in rural markets.
Rare Disease Therapies: Brands fund genetic testing awareness and educate pediatricians on symptom recognition to shorten the “diagnostic odyssey.”

6. Building Your Pre-Launch Roadmap

Success requires structured execution across four critical phases:

Phase 1 (Months 18-24): Competitive Intelligence and Gap Analysis. Establish the clinical narrative your market shaping will address.
Phase 2 (Months 12-18): Unbranded Disease Education. Launch CME programs and publish epidemiological data to build clinical urgency.
Phase 3 (Months 6-12): HCP Priming and KOL Engagement. Provide clinical trial updates and facilitate peer discussions with early adopters.
Phase 4 (Months 0-6): Launch Readiness. Transition educated HCPs to product-specific evidence and activate sales teams.

The Strategic Conclusion

Market shaping transforms drug launch outcomes by eliminating the educational lag between regulatory approval and prescriber adoption. Pharma brands that invest in pre-launch planning capture HCP mindshare before competitors recognize the opportunity. This timing advantage translates directly into prescription volume and market share.

OneAlphaMed helps pharmaceutical brand teams build market shaping roadmaps that inform every stage of launch planning. Explore Brand Strategy & Product Launch →

Frequently Asked Questions

What is market shaping in pharma?

Market shaping creates prescriber demand before regulatory approval by educating HCPs on disease burden, identifying diagnosis gaps, and priming treatment pathways through unbranded disease education. This pre-launch planning strategy operates 18-24 months before approval to build launch readiness.

How does market shaping differ from disease awareness campaigns?

Disease awareness targets patients post-launch to drive consultation requests. Market shaping targets prescribers pre-launch to establish clinical urgency and treatment readiness. Timing separates these strategies: disease awareness begins after approval; market shaping operates before approval using unbranded education.

When should pharma brands start market shaping activities?

Leading Indian pharma companies launch market shaping during Phase 3 trials, 18-24 months before expected DCGI approval. This timing enables competitive intelligence gathering, diagnosis gap analysis, HCP priming strategy, and unbranded disease education to reach prescribers before competitors recognize the opportunity.

What are the core components of a market shaping strategy?

Effective market shaping combines diagnosis gap analysis (quantifying undertreated populations), competitive intelligence (understanding current treatment patterns), unbranded disease education (building HCP awareness without product promotion), and HCP priming strategy (engaging early adopters before launch). These components create prescriber readiness when approval arrives.